5-Fluorouracil Altered Morphology and Inhibited Growth of
            <i>Candida albicans</i>

Kesavan, Chandrasekhar; Joyee, Antony George

doi:10.1128/jcm.43.12.6215-6216.2005

Cited by 9 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other antitumour drugs, including 5-fluorouracil, selenium, coumarin and 1,10-phenanthroline, have been described as cytotoxic agents that lead to yeast cell death [92][93][94][95][96][97]. However, the mechanism of the cell death process underlying their cytotoxicity remains unexplored.…”

Section: Cytotoxicity Of Antitumour Drugs In Yeastmentioning

confidence: 99%

Drug-induced apoptosis in yeast

Almeida

Silva

Mesquita

et al. 2008

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

View full text Add to dashboard Cite

In order to alter the impact of diseases on human society, drug development has been one of the most invested research fields. Nowadays, cancer and infectious diseases are leading targets for the design of effective drugs, in which the primary mechanism of action relies on the modulation of programmed cell death (PCD). Due to the high degree of conservation of basic cellular processes between yeast and higher eukaryotes, and to the existence of an ancestral PCD machinery in yeast, yeasts are an attractive tool for the study of affected pathways that give insights into the mode of action of both antitumour and antifungal drugs. Therefore, we covered some of the leading reports on drug-induced apoptosis in yeast, revealing that in common with mammalian cells, antitumour drugs induce apoptosis through reactive oxygen species (ROS) generation and altered mitochondrial functions. The evidence presented suggests that yeasts may be a powerful model for the screening/development of PCD-directed drugs, overcoming the problem of cellular specificity in the design of antitumour drugs, but also enabling the design of efficient antifungal drugs, targeted to fungal-specific apoptotic regulators that do not have major consequences for human cells.

show abstract

Section: Cytotoxicity Of Antitumour Drugs In Yeastmentioning

confidence: 99%

Drug-induced apoptosis in yeast

Almeida

Silva

Mesquita

et al. 2008

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

View full text Add to dashboard Cite

show abstract

“…It was shown that positive and negative interactive effects occurred among antifungal and antineoplastic drugs, which contributed to variations in the concentration of antifungal required to inhibit the growth of Candida species [21,22]. Cisplatin and 5-fluorouracil were shown to alter the morphology and growth of C. albicans [23,24]. Recently, tamoxifen and its structural analog clomiphene were shown to possess good anti- Candida activities in vitro and in vivo in a mouse model [25].…”

Section: Introductionmentioning

confidence: 99%

Dual Properties of Anticancer Agents: An Exploratory Study on the in vitro Anti-Candida Properties of Thirty Drugs

Routh

Raut

Karuppayil³

2011

Chemotherapy

View full text Add to dashboard Cite

Background: Anticancer/antineoplastic agents could be a good resource for the discovery of novel antifungal agents and targets since human beings share a common eukaryotic heritage with fungi. Methods: Thirty commonly prescribed anticancer drugs belonging to 12 different classes were analyzed for their effects on the growth of Candida albicans. Minimum inhibitory concentrations (MICs) were obtained using standard CLSI-M27 A2 methodology, and minimal fungicidal concentrations (MFCs) were determined via the agar plate method. Results: Anticancer agents inhibited the growth of C. albicans in a concentration-dependent manner. Nine drugs from different classes were effective at low concentrations (≤50 µg·ml^–1), while 15 anticancer drugs exhibited MICs of 100 µg·ml^–1. Sixteen out of 30 drugs exerted fungicidal activity in the range of 400–800 µg·ml^–1. Conclusions: MICs and MFCs for 30 anticancer drugs were established against C. albicans. Our study highlighted the anti-Candida potential of these drugs, which may give insights to unexplored targets for antifungal chemotherapy.

show abstract

Current awareness on yeast

2006

Yeast

View full text Add to dashboard Cite

The diagnosis of Angelman syndrome (AS) can be confirmed by genetic laboratory in about 80% of cases. In 20%, the diagnosis remains clinical, but often there is uncertainty about the correctness of the clinical diagnosis and alternative diagnoses may be investigated. In evaluating individuals for AS in our center since 1989, we have encountered several mimicking conditions, and additional ones have been reported in the literature. Mimicking conditions can be grouped into the areas of chromosome, single gene, and symptom complex anomalies. Microdeletions or microduplications include chromosome regions 2,4,17, 22, and 15. Single gene conditions include methylene tetrahydrofolate reductase deficiency (MTHFR), Rett syndrome, alpha‐thalassemia retardation syndrome (ATR‐X), and Gurrieri syndrome. Symptom complexes include cerebral palsy, static encephalopathy, Lennox‐Gastaut syndrome, autism spectrum disorder, pervasive developmental delay (PDD), and mitochondrial disorders. We present a review of these mimicking disorders to increase the awareness about conditions that can lead to an incorrect clinical diagnosis of AS. © 2001 Wiley‐Liss, Inc.

show abstract

5-Fluorouracil Altered Morphology and Inhibited Growth of Candida albicans

Cited by 9 publications

References 4 publications

Drug-induced apoptosis in yeast

Drug-induced apoptosis in yeast

Dual Properties of Anticancer Agents: An Exploratory Study on the in vitro Anti-Candida Properties of Thirty Drugs

Current awareness on yeast

Contact Info

Product

Resources

About